Comparison of strength testing modalities in dysferlinopathy
Introduction/Aims Dysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing muscle strength due to disease progression or from an investigational product is associated with changing functional ability. The purpose of thi...
Saved in:
Published in | Muscle & nerve Vol. 66; no. 2; pp. 159 - 166 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.08.2022
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Introduction/Aims
Dysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing muscle strength due to disease progression or from an investigational product is associated with changing functional ability. The purpose of this study was to compare three methods of strength testing used in the Clinical Outcome Study (COS) for dysferlinopathy to understand which method and which muscle groups were most sensitive to change over time.
Methods
Patients were evaluated at each study visit using functional scales, manual muscle testing, and handheld dynamometry (HHD) at all 15 sites. A fixed‐frame system (Fixed) was used at a subset of seven sites. Screening and baseline visits were evaluated for reliability. Data over a 1‐year period were analyzed to determine sensitivity to change among strength modalities and individual muscle groups.
Results
HHD and Fixed captured significant change across 1 year in summed muscle strength score of four muscle groups (P < .01). Strength summed scores were significantly correlated with functional scales (rho = 0.68‐0.92, P < .001). Individual muscle groups, however, showed high levels of variability between visits.
Discussion
Although both HHD and Fixed demonstrate change over 12 months, HHD is a less expensive option that provides data on a continuous scale and may be easier to implement. Due to variability in strength measures, researchers should carefully consider use of strength testing as an outcome and may wish to select functional measures with less variability as clinical trial endpoints. |
---|---|
AbstractList | Abstract
Introduction/Aims
Dysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing muscle strength due to disease progression or from an investigational product is associated with changing functional ability. The purpose of this study was to compare three methods of strength testing used in the Clinical Outcome Study (COS) for dysferlinopathy to understand which method and which muscle groups were most sensitive to change over time.
Methods
Patients were evaluated at each study visit using functional scales, manual muscle testing, and handheld dynamometry (HHD) at all 15 sites. A fixed‐frame system (Fixed) was used at a subset of seven sites. Screening and baseline visits were evaluated for reliability. Data over a 1‐year period were analyzed to determine sensitivity to change among strength modalities and individual muscle groups.
Results
HHD and Fixed captured significant change across 1 year in summed muscle strength score of four muscle groups (
P
< .01). Strength summed scores were significantly correlated with functional scales (rho = 0.68‐0.92,
P
< .001). Individual muscle groups, however, showed high levels of variability between visits.
Discussion
Although both HHD and Fixed demonstrate change over 12 months, HHD is a less expensive option that provides data on a continuous scale and may be easier to implement. Due to variability in strength measures, researchers should carefully consider use of strength testing as an outcome and may wish to select functional measures with less variability as clinical trial endpoints. Introduction/AimsDysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing muscle strength due to disease progression or from an investigational product is associated with changing functional ability. The purpose of this study was to compare three methods of strength testing used in the Clinical Outcome Study (COS) for dysferlinopathy to understand which method and which muscle groups were most sensitive to change over time.MethodsPatients were evaluated at each study visit using functional scales, manual muscle testing, and handheld dynamometry (HHD) at all 15 sites. A fixed‐frame system (Fixed) was used at a subset of seven sites. Screening and baseline visits were evaluated for reliability. Data over a 1‐year period were analyzed to determine sensitivity to change among strength modalities and individual muscle groups.ResultsHHD and Fixed captured significant change across 1 year in summed muscle strength score of four muscle groups (P < .01). Strength summed scores were significantly correlated with functional scales (rho = 0.68‐0.92, P < .001). Individual muscle groups, however, showed high levels of variability between visits.DiscussionAlthough both HHD and Fixed demonstrate change over 12 months, HHD is a less expensive option that provides data on a continuous scale and may be easier to implement. Due to variability in strength measures, researchers should carefully consider use of strength testing as an outcome and may wish to select functional measures with less variability as clinical trial endpoints. Dysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing muscle strength due to disease progression or from an investigational product is associated with changing functional ability. The purpose of this study was to compare three methods of strength testing used in the Clinical Outcome Study (COS) for dysferlinopathy to understand which method and which muscle groups were most sensitive to change over time. Patients were evaluated at each study visit using functional scales, manual muscle testing, and handheld dynamometry (HHD) at all 15 sites. A fixed-frame system (Fixed) was used at a subset of seven sites. Screening and baseline visits were evaluated for reliability. Data over a 1-year period were analyzed to determine sensitivity to change among strength modalities and individual muscle groups. HHD and Fixed captured significant change across 1 year in summed muscle strength score of four muscle groups (P < .01). Strength summed scores were significantly correlated with functional scales (rho = 0.68-0.92, P < .001). Individual muscle groups, however, showed high levels of variability between visits. Although both HHD and Fixed demonstrate change over 12 months, HHD is a less expensive option that provides data on a continuous scale and may be easier to implement. Due to variability in strength measures, researchers should carefully consider use of strength testing as an outcome and may wish to select functional measures with less variability as clinical trial endpoints. Introduction/Aims Dysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing muscle strength due to disease progression or from an investigational product is associated with changing functional ability. The purpose of this study was to compare three methods of strength testing used in the Clinical Outcome Study (COS) for dysferlinopathy to understand which method and which muscle groups were most sensitive to change over time. Methods Patients were evaluated at each study visit using functional scales, manual muscle testing, and handheld dynamometry (HHD) at all 15 sites. A fixed‐frame system (Fixed) was used at a subset of seven sites. Screening and baseline visits were evaluated for reliability. Data over a 1‐year period were analyzed to determine sensitivity to change among strength modalities and individual muscle groups. Results HHD and Fixed captured significant change across 1 year in summed muscle strength score of four muscle groups (P < .01). Strength summed scores were significantly correlated with functional scales (rho = 0.68‐0.92, P < .001). Individual muscle groups, however, showed high levels of variability between visits. Discussion Although both HHD and Fixed demonstrate change over 12 months, HHD is a less expensive option that provides data on a continuous scale and may be easier to implement. Due to variability in strength measures, researchers should carefully consider use of strength testing as an outcome and may wish to select functional measures with less variability as clinical trial endpoints. |
Author | Yajima, Hiroyuki Bushby, Kate Lowes, Linda P. Rufibach, Laura E. Holsten, Scott Wolf, Brittney Duong, Tina Gee, Richard Straub, Volker Alfano, Lindsay N. Mori‐Yoshimura, Madoka Bravver, Elena Mayhew, Anna G. James, Meredith K. Sakamoto, Chikako Tateishi, Takayuki Jacobs, Marni Iammarino, Megan A. Bharucha‐Goebel, Diana X. Reash, Natalie F. |
Author_xml | – sequence: 1 givenname: Natalie F. orcidid: 0000-0002-0573-9504 surname: Reash fullname: Reash, Natalie F. email: natalie.reash@nationwidechildrens.org organization: The Abigail Wexner Research Institute at Nationwide Children's Hospital – sequence: 2 givenname: Meredith K. orcidid: 0000-0001-8078-7744 surname: James fullname: James, Meredith K. organization: Newcastle University and Newcastle Hospitals NHS Foundation Trust – sequence: 3 givenname: Lindsay N. surname: Alfano fullname: Alfano, Lindsay N. organization: The Abigail Wexner Research Institute at Nationwide Children's Hospital – sequence: 4 givenname: Anna G. surname: Mayhew fullname: Mayhew, Anna G. organization: Newcastle University and Newcastle Hospitals NHS Foundation Trust – sequence: 5 givenname: Marni orcidid: 0000-0001-6649-6692 surname: Jacobs fullname: Jacobs, Marni organization: George Washington University – sequence: 6 givenname: Megan A. surname: Iammarino fullname: Iammarino, Megan A. organization: The Abigail Wexner Research Institute at Nationwide Children's Hospital – sequence: 7 givenname: Scott surname: Holsten fullname: Holsten, Scott organization: Carolinas HealthCare System – sequence: 8 givenname: Chikako surname: Sakamoto fullname: Sakamoto, Chikako organization: National Center of Neurology and Psychiatry – sequence: 9 givenname: Takayuki surname: Tateishi fullname: Tateishi, Takayuki organization: National Center of Neurology and Psychiatry – sequence: 10 givenname: Hiroyuki surname: Yajima fullname: Yajima, Hiroyuki organization: National Center of Neurology and Psychiatry – sequence: 11 givenname: Tina surname: Duong fullname: Duong, Tina organization: Stanford University School of Medicine – sequence: 12 givenname: Brittney surname: Wolf fullname: Wolf, Brittney organization: Children's National Health System – sequence: 13 givenname: Richard surname: Gee fullname: Gee, Richard organization: Lucile Salter Packard Children's Hospital at Stanford, Neurology – sequence: 14 givenname: Diana X. surname: Bharucha‐Goebel fullname: Bharucha‐Goebel, Diana X. organization: National Institute of Neurological Disorders and Stroke, National Institutes of Health – sequence: 15 givenname: Elena surname: Bravver fullname: Bravver, Elena organization: Carolinas HealthCare System – sequence: 16 givenname: Madoka surname: Mori‐Yoshimura fullname: Mori‐Yoshimura, Madoka organization: National Center of Neurology and Psychiatry – sequence: 17 givenname: Kate surname: Bushby fullname: Bushby, Kate organization: Newcastle University and Newcastle Hospitals NHS Foundation Trust – sequence: 18 givenname: Laura E. surname: Rufibach fullname: Rufibach, Laura E. organization: The Jain Foundation – sequence: 19 givenname: Volker orcidid: 0000-0001-9046-3540 surname: Straub fullname: Straub, Volker organization: Newcastle University and Newcastle Hospitals NHS Foundation Trust – sequence: 20 givenname: Linda P. surname: Lowes fullname: Lowes, Linda P. organization: The Abigail Wexner Research Institute at Nationwide Children's Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35506767$$D View this record in MEDLINE/PubMed |
BookMark | eNp10M1LwzAYx_EgE_eiB_8BKXjRQ92TpkkW8CLDN5h40IG3kjXJltEmM2mR_fd2bHoQPD2XD19-PEPUc95phM4x3GCAbFy38SbjlMMRGmAQPM2pmPTQAHA-SRkRH300jHENAHjC-AnqE0qBccYH6Hbq640MNnqXeJPEJmi3bFZJo2Nj3TKpvZKVbayOiXWJ2kajQ2Wd38hmtT1Fx0ZWUZ8d7gjNH-7fp0_p7PXxeXo3S0tCCaRZjnEmpTaKYWqyhS6ZMkpmoCjPSwYGc16WRHGKJ8JobXLIRam6iQsBICUZoat9dxP8Z9stK2obS11V0mnfxiJjVDAgmJKOXv6ha98G163rlMCC5DiDTl3vVRl8jEGbYhNsLcO2wFDsXlrUu-zupZ29OBTbRa3Vr_z5YQfGe_BlK739v1S8zN_2yW_CgYIC |
CitedBy_id | crossref_primary_10_1186_s12883_024_03588_1 crossref_primary_10_19163_2307_9266_2022_10_5_483_496 |
Cites_doi | 10.2519/jospt.1991.13.4.191 10.1212/WNL.0000000000007265 10.1515/med-2017-0052 10.1213/ANE.0000000000002864 10.1016/S0895-4356(99)00206-1 10.1002/mus.25045 10.1002/mus.21544 10.1002/ana.26044 10.1007/BF00313939 10.1161/STROKEAHA.108.530584 10.1212/WNL.44.3_Part_1.442 10.1001/jamaneurol.2020.1484 10.1038/1689 10.1016/j.omtn.2018.08.013 10.1093/brain/109.1.31 10.1002/mus.20654 10.1212/NXG.0000000000000089 10.1016/j.nmd.2021.01.009 10.1212/WNL.0b013e3181ea1564 10.1001/jamaneurol.2020.1264 10.1186/1750-1172-8-26 10.1371/journal.pone.0219854 10.1089/hum.2017.062 10.1038/1682 10.1136/jnnp-2017-317488 10.1089/hum.2019.006 10.1055/s-0034-1396008 10.1002/acn3.51235 10.1212/WNL.0000000000006858 |
ContentType | Journal Article |
Copyright | 2022 Wiley Periodicals LLC. |
Copyright_xml | – notice: 2022 Wiley Periodicals LLC. |
CorporateAuthor | Jain COS Consortium for the Jain COS Consortium |
CorporateAuthor_xml | – name: Jain COS Consortium – name: for the Jain COS Consortium |
DBID | NPM AAYXX CITATION 7T5 7TK 7TM 7TS 7U7 7U9 C1K H94 K9. NAPCQ 7X8 |
DOI | 10.1002/mus.27570 |
DatabaseName | PubMed CrossRef Immunology Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Physical Education Index Toxicology Abstracts Virology and AIDS Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef Nursing & Allied Health Premium Virology and AIDS Abstracts Toxicology Abstracts Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Neurosciences Abstracts Physical Education Index Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | CrossRef Nursing & Allied Health Premium MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-4598 |
EndPage | 166 |
ExternalDocumentID | 10_1002_mus_27570 35506767 MUS27570 |
Genre | article Journal Article |
GrantInformation_xml | – fundername: Jain Foundation – fundername: Medical Research Council funderid: MR/K000608/1 – fundername: NIHR Newcastle Biomedical Research Centre – fundername: Medical Research Council grantid: MR/K000608/1 |
GroupedDBID | --- -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 123 1CY 1L6 1OB 1OC 1ZS 31~ 33P 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AAQQT AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRMAN DRSTM EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC FYBCS G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6M MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWD RWI RX1 RYL SAMSI SUPJJ SV3 TEORI TUS TWZ UB1 V2E W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 XPP XV2 YCJ ZGI ZXP ZZTAW ~IA ~WT NPM AAYXX CITATION 7T5 7TK 7TM 7TS 7U7 7U9 C1K H94 K9. NAPCQ 7X8 |
ID | FETCH-LOGICAL-c3530-24112aaefd615f2bec6dfda20d574c60f177cc3d75189feef4049cd506b900aa3 |
IEDL.DBID | DR2 |
ISSN | 0148-639X |
IngestDate | Fri Aug 16 01:27:42 EDT 2024 Thu Oct 10 22:18:26 EDT 2024 Fri Aug 23 04:04:52 EDT 2024 Sat Sep 28 08:19:31 EDT 2024 Sat Aug 24 01:02:56 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | outcome measure handheld dynamometry strength limb girdle muscular dystrophy dysferlinopathy |
Language | English |
License | 2022 Wiley Periodicals LLC. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3530-24112aaefd615f2bec6dfda20d574c60f177cc3d75189feef4049cd506b900aa3 |
Notes | Funding information Jain Foundation; Medical Research Council, Grant/Award Number: MR/K000608/1; NIHR Newcastle Biomedical Research Centre Elena Bravver deceased. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-9046-3540 0000-0001-6649-6692 0000-0002-0573-9504 0000-0001-8078-7744 |
PMID | 35506767 |
PQID | 2691934120 |
PQPubID | 1016420 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_2659603153 proquest_journals_2691934120 crossref_primary_10_1002_mus_27570 pubmed_primary_35506767 wiley_primary_10_1002_mus_27570_MUS27570 |
PublicationCentury | 2000 |
PublicationDate | August 2022 |
PublicationDateYYYYMMDD | 2022-08-01 |
PublicationDate_xml | – month: 08 year: 2022 text: August 2022 |
PublicationDecade | 2020 |
PublicationPlace | Hoboken, USA |
PublicationPlace_xml | – name: Hoboken, USA – name: United States – name: Rochester |
PublicationTitle | Muscle & nerve |
PublicationTitleAlternate | Muscle Nerve |
PublicationYear | 2022 |
Publisher | John Wiley & Sons, Inc Wiley Subscription Services, Inc |
Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc |
References | 2018; 29 2010; 75 2019; 92 2009; 40 2021; 89 2019; 30 1991; 13 2018; 126 2019; 14 2016; 54 1976 1994; 44 2020; 77 2018; 89 2013; 8 1998; 20 2003; 30 2007; 35 2010; 41 2020; 7 1986; 109 1984; 231 2021; 31 2016; 2 2000; 53 2017; 12 2014; 34 2018; 13 e_1_2_12_4_1 e_1_2_12_3_1 e_1_2_12_6_1 e_1_2_12_5_1 e_1_2_12_18_1 e_1_2_12_2_1 e_1_2_12_17_1 e_1_2_12_16_1 e_1_2_12_20_1 e_1_2_12_21_1 e_1_2_12_22_1 e_1_2_12_23_1 e_1_2_12_24_1 e_1_2_12_25_1 e_1_2_12_26_1 e_1_2_12_27_1 Rider LG (e_1_2_12_28_1) 2003; 30 e_1_2_12_29_1 e_1_2_12_30_1 e_1_2_12_31_1 e_1_2_12_32_1 e_1_2_12_15_1 e_1_2_12_14_1 e_1_2_12_13_1 e_1_2_12_12_1 e_1_2_12_8_1 e_1_2_12_11_1 Medical Research Council (e_1_2_12_19_1) 1976 e_1_2_12_7_1 e_1_2_12_10_1 e_1_2_12_9_1 |
References_xml | – volume: 54 start-page: 203 year: 2016 end-page: 210 article-title: Broadening the imaging phenotype of dysferlinopathy at different disease stages publication-title: Muscle Nerve – volume: 109 start-page: 31 year: 1986 end-page: 54 article-title: Autosomal recessive distal muscular dystrophy as a new type of progressive muscular dystrophy. Seventeen cases in eight families including an autopsied case publication-title: Brain – volume: 14 year: 2019 article-title: Intraclass correlation‐‐‐a discussion and demonstration of basic features publication-title: PLoS One – volume: 8 start-page: 26 year: 2013 article-title: Treatment of dysferlinopathy with deflazacort: a double‐blind, placebo‐controlled clinical trial publication-title: Orphanet J Rare Dis – volume: 2 year: 2016 article-title: The clinical outcome study for dysferlinopathy: an international multicenter study publication-title: Neurol Genet – volume: 20 start-page: 37 year: 1998 end-page: 42 article-title: A gene related to spermatogenesis factor fer‐1 is mutated in limb‐girdle muscular dystrophy type 2B publication-title: Nat Genet – volume: 30 start-page: 794 year: 2019 end-page: 801 article-title: Gene delivery for limb‐girdle muscular dystrophy type 2D by isolated limb infusion publication-title: Hum Gene Ther – volume: 53 start-page: 459 year: 2000 end-page: 468 article-title: Methods for assessing responsiveness: a critical review and recommendations publication-title: J Clin Epidemiol – volume: 29 start-page: 749 year: 2018 end-page: 762 article-title: Systemic delivery of dysferlin overlap vectors provides long‐term gene expression and functional improvement for dysferlinopathy publication-title: Hum Gene Ther – volume: 13 start-page: 198 year: 2018 end-page: 207 article-title: Exon skipping in a Dysf‐missense mutant mouse model publication-title: Mol Ther Nucleic Acids – volume: 126 start-page: 1763 year: 2018 end-page: 1768 article-title: Correlation coefficients: appropriate use and interpretation publication-title: Anesth Analg – volume: 7 start-page: 2393 year: 2020 end-page: 2408 article-title: Viltolarsen in Japanese Duchenne muscular dystrophy patients: a phase 1/2 study publication-title: Ann Clin Transl Neurol – volume: 44 start-page: 442 year: 1994 end-page: 446 article-title: Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing publication-title: Neurology – volume: 40 start-page: 1386 year: 2009 end-page: 1391 article-title: Responsiveness and validity of three outcome measures of motor function after stroke rehabilitation publication-title: Stroke – volume: 92 start-page: e461 year: 2019 end-page: e474 article-title: Assessment of disease progression in dysferlinopathy: a 1‐year cohort study publication-title: Neurology – volume: 35 start-page: 36 year: 2007 end-page: 42 article-title: Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy publication-title: Muscle Nerve – volume: 20 start-page: 31 year: 1998 end-page: 36 article-title: Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy publication-title: Nat Genet – volume: 75 start-page: 316 year: 2010 end-page: 323 article-title: Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies publication-title: Neurology – volume: 92 start-page: e1773 year: 2019 end-page: e1785 article-title: Community exercise is feasible for neuromuscular diseases and can improve aerobic capacity publication-title: Neurology – volume: 30 start-page: 603 year: 2003 end-page: 617 article-title: Defining clinical improvement in adult and juvenile myositis publication-title: J Rheumatol – volume: 77 start-page: 982 year: 2020 end-page: 991 article-title: Safety, tolerability, and efficacy of Viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial publication-title: JAMA Neurol – volume: 89 start-page: 1071 year: 2018 end-page: 1081 article-title: Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials publication-title: J Neurol Neurosurg Psychiatry – volume: 231 start-page: 200 year: 1984 end-page: 203 article-title: Measuring muscle strength publication-title: J Neurol – volume: 12 start-page: 359 year: 2017 end-page: 375 article-title: Absolute reliability and concurrent validity of hand held dynamometry and isokinetic dynamometry in the hip, knee and ankle joint: systematic review and meta‐analysis publication-title: Open Med (Wars) – volume: 41 start-page: 500 year: 2010 end-page: 510 article-title: The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy publication-title: Muscle Nerve – volume: 89 start-page: 967 year: 2021 end-page: 978 article-title: Assessing Dysferlinopathy patients over three years with a new motor scale publication-title: Ann Neurol – volume: 13 start-page: 191 year: 1991 end-page: 198 article-title: Hand‐held dynamometer measurements: tester strength makes a difference publication-title: J Orthop Sports Phys Ther – volume: 34 start-page: 542 year: 2014 end-page: 556 article-title: Exercise in neuromuscular disease publication-title: Semin Neurol – year: 1976 – volume: 31 start-page: 265 year: 2021 end-page: 280 article-title: Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same disease publication-title: Neuromuscul Disord. – volume: 77 start-page: 1122 year: 2020 end-page: 1131 article-title: Assessment of systemic delivery of rAAVrh74.MHCK7.Micro‐dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial publication-title: JAMA Neurol – ident: e_1_2_12_29_1 doi: 10.2519/jospt.1991.13.4.191 – volume-title: Aids to the Investigation of Peripheral Nerve Injuries year: 1976 ident: e_1_2_12_19_1 contributor: fullname: Medical Research Council – ident: e_1_2_12_32_1 doi: 10.1212/WNL.0000000000007265 – ident: e_1_2_12_27_1 doi: 10.1515/med-2017-0052 – ident: e_1_2_12_24_1 doi: 10.1213/ANE.0000000000002864 – ident: e_1_2_12_25_1 doi: 10.1016/S0895-4356(99)00206-1 – ident: e_1_2_12_6_1 doi: 10.1002/mus.25045 – ident: e_1_2_12_23_1 doi: 10.1002/mus.21544 – ident: e_1_2_12_17_1 doi: 10.1002/ana.26044 – ident: e_1_2_12_20_1 doi: 10.1007/BF00313939 – ident: e_1_2_12_26_1 doi: 10.1161/STROKEAHA.108.530584 – ident: e_1_2_12_22_1 doi: 10.1212/WNL.44.3_Part_1.442 – ident: e_1_2_12_13_1 doi: 10.1001/jamaneurol.2020.1484 – volume: 30 start-page: 603 year: 2003 ident: e_1_2_12_28_1 article-title: Defining clinical improvement in adult and juvenile myositis publication-title: J Rheumatol contributor: fullname: Rider LG – ident: e_1_2_12_2_1 doi: 10.1038/1689 – ident: e_1_2_12_15_1 doi: 10.1016/j.omtn.2018.08.013 – ident: e_1_2_12_4_1 doi: 10.1093/brain/109.1.31 – ident: e_1_2_12_21_1 doi: 10.1002/mus.20654 – ident: e_1_2_12_5_1 doi: 10.1212/NXG.0000000000000089 – ident: e_1_2_12_9_1 doi: 10.1016/j.nmd.2021.01.009 – ident: e_1_2_12_8_1 doi: 10.1212/WNL.0b013e3181ea1564 – ident: e_1_2_12_10_1 doi: 10.1001/jamaneurol.2020.1264 – ident: e_1_2_12_14_1 doi: 10.1186/1750-1172-8-26 – ident: e_1_2_12_30_1 doi: 10.1371/journal.pone.0219854 – ident: e_1_2_12_16_1 doi: 10.1089/hum.2017.062 – ident: e_1_2_12_3_1 doi: 10.1038/1682 – ident: e_1_2_12_7_1 doi: 10.1136/jnnp-2017-317488 – ident: e_1_2_12_12_1 doi: 10.1089/hum.2019.006 – ident: e_1_2_12_31_1 doi: 10.1055/s-0034-1396008 – ident: e_1_2_12_11_1 doi: 10.1002/acn3.51235 – ident: e_1_2_12_18_1 doi: 10.1212/WNL.0000000000006858 |
SSID | ssj0001867 |
Score | 2.443585 |
Snippet | Introduction/Aims
Dysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing... Dysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing muscle strength due... Abstract Introduction/Aims Dysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time.... Introduction/AimsDysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing... INTRODUCTION/AIMSDysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 159 |
SubjectTerms | dysferlinopathy Evaluation handheld dynamometry Heterogeneity limb girdle muscular dystrophy Muscle strength outcome measure Patients Reliability analysis Sensitivity analysis strength Strength testing Variability |
Title | Comparison of strength testing modalities in dysferlinopathy |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fmus.27570 https://www.ncbi.nlm.nih.gov/pubmed/35506767 https://www.proquest.com/docview/2691934120 https://search.proquest.com/docview/2659603153 |
Volume | 66 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEB7Eg3jx_VhdpYoHL91t06Rp0IuoyyLoQV3Yg1DSplERW3G7h_XXO0m3XVQE8daSpmkzmc43zcw3AEeKSkGThLpcSeFS5kduRPAU0aufcWGSL22U703YH9CrIRvOwUmdC1PxQzQ_3Ixm2O-1UXCZjLoz0tDX8ahDOOPGX_cDbsK5Lm5n1FGGqK0KX4xctMLDmlXII92m51db9ANgfsWr1uD0luGhftQqzuSlMy6TTvrxjcXxn--yAktTIOqcVStnFeayfA0Wrqdb7etwet5UKHQK7ZickvyxfHJKQ8uRPzqvhTIQHh1t5zl31GSkLXFWYUocTzZg0Lu8P--701ILbhqwwHPRjvtEykwrRDiaoGBDpZUknmKcpqGnfc7TNFBmk0boLNMUPYtUMS9MhOdJGWzCfF7k2TY4OtKJIoJKP0qolqGMJN6I8FQQhfiCteCwnvT4rWLUiCvuZBLjPMR2HlrQrsURT5UKW0KBcJP6BJsPmmZUB7PHIfOsML1DJkzhbBa0YKsSYzMKQivP8NO14NgK4_fh4-vBnT3Y-fulu7BITGqEDQ5sw3z5Ps72ELCUyb5dmZ_jO-ZE |
link.rule.ids | 315,783,787,1378,27938,27939,46308,46732 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT4QwEJ4YTdSL78fqqmg8eGGF0gJNvJhVs-quB3WTvRhSKFVjBKPsQX-907JgVmNivEFKael0mK_tzDcA-5IKTuOY2oEU3KbMDe2Q4C2iVzcNuA6-NF6-V36nTy8GbDABR1UsTMkPUW-4ac0w_2ut4HpD-vCLNfR5-NYiAQtwwT6F6u7p_AUn11_kUZqqrXRgDG20w4OKV8ghh3XVcWv0A2KOI1Zjcs7m4a7qbOlp8tQaFnEr-fjG4_jfr1mAuREWtY7LybMIE2m2BNO90Wn7Mhy16ySFVq4sHVaS3RcPVqGZObJ76zmXGsXjWtt6zCz5_qYMd1ausxy_r0D_7PS23bFH2RbsxGOeY6Mpd4kQqZIIchRB2fpSSUEcyQKa-I5ygyBJPKnPabhKU0VxcZFI5vgxdxwhvFWYzPIsXQdLhSqWhFPhhjFVwhehwBeRIOFEIsRgDdirRj16KUk1opI-mUQ4DpEZhwY0K3lEI73CEp8j4qQuweLduhg1Qh9ziCzNdW2fcZ07m3kNWCvlWLeC6MrRFHUNODDS-L35qNe_MRcbf390B2Y6t71u1D2_utyEWaIjJYyvYBMmi9dhuoX4pYi3zTT9BERE6l4 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT4QwEJ4YTYwX34_1icaDF9ZSWqDRi1E3vmPUTfZgQgqlaoxglD3or3daFowaE-MNUkqh02G-oTPfAGwqJgVLEuaGSgqXcS9yI4qniF69LBQm-dJG-V4ER1120uO9Idipc2Eqfojmh5vRDPu9Ngr-rPT2J2noU_-1TUMeor8-wgKfmHiug6tP7ijD1FbFL0YumuFeTStE6HbT9asx-oEwvwJWa3E6E3BbP2sVaPLY7pdJO33_RuP4z5eZhPEBEnX2qqUzBUNZPg2j54O99hnY3W9KFDqFdkxSSX5X3jul4eXI75ynQhkMj56285A76u1VW-aswtQ4fpuFbufwZv_IHdRacFOf-8RFQ-5RKTOtEOJoipINlFaSEsVDlgZEe2GYpr4yuzRCZ5lm6FqkipMgEYRI6c_BcF7k2QI4OtKJooJJL0qYloGMJN6IhqmgCgEGb8FGPenxc0WpEVfkyTTGeYjtPLRguRZHPNAqbAkE4k3mUWxeb5pRH8wmh8yzwvQOuDCVs7nfgvlKjM0oiK2IIahrwZYVxu_Dx-fda3uw-PdL12D08qATnx1fnC7BGDVpEjZQcBmGy5d-toLgpUxW7SL9AJ4V6Q0 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+strength+testing+modalities+in+dysferlinopathy&rft.jtitle=Muscle+%26+nerve&rft.au=Reash%2C+Natalie+F&rft.au=James%2C+Meredith+K&rft.au=Alfano%2C+Lindsay+N&rft.au=Mayhew%2C+Anna+G&rft.date=2022-08-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0148-639X&rft.eissn=1097-4598&rft.volume=66&rft.issue=2&rft.spage=159&rft.epage=166&rft_id=info:doi/10.1002%2Fmus.27570&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0148-639X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0148-639X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0148-639X&client=summon |